Clinical Trial Details

Trial ID: L0550
Source ID: JPRN-UMIN000027058
Associated Drug: Kestose
Title: Usefulness of kestose for the patients with NAFLD and NASH - Treatment with kestose for NAFLD/NASH
Acronym: --
Status: Recruiting
Study Results: No Results Available
Results: --
Conditions: Nonalcoholic fatty liver disease/Nonalcoholic steatohepatitis
Interventions: kestose<br>placebo
Outcome Measures: Improvement of liver enzyme1.Changes of short-chain fatty acid (Butyric acid,Acetic acid,Propionic acid etc.)<br>2.Changes of pathologic and metabolic marker (HOMA-IR, NAFIC socre, NAFLD fibrosis sore, FIB-4 index, APRI index, T.Cho, LDL-Cho, HDL-Cho, TG, FFA, ferritin, fasting glucose,HbA1c, high sensitivity CRP etc.)<br>3.Changes of hepatic fibrosis markers<br>4.Changes of degree of fatty liver by abdominal ultrasound examination<br>5.Correlation of gut microbiota and therapeutic effect<br>6.Changes of body weight and BMI<br>7.Metabolome and protein analysis of metabolite in feces<br>8.Changes of bile acid<br>9.Correlation between expiratory noble gases, gut microbiota and NAFLD/NASH<br>10.Correlation between usefulness of kestose and disease prognosis in the patients with NAFLD/NASH
Sponsor/Collaborators: Nagoya University Hospital
Gender: All
Age: 20years-oldNot applicable
Phases: Not selected
Enrollment: 60
Study Type: Interventional
Study Designs: Parallel Randomized
Start Date: 27/04/2017
Completion Date: 30/03/2027
Results First Posted: --
Last Update Posted: 5 November 2019
Locations: Japan
URL: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030944

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D195 Kestose Chemical drug -- -- -- Under clinical trials Details